Literature DB >> 22477819

Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics.

Michael D Reed1.   

Abstract

The need for critical, well-designed comprehensive clinical pharmacology research in pediatrics that encompasses the age continuum, from the most premature infant through adolescence, may be more important today than ever. New drug regimens often require greater adherence to specific dose guidelines to maximize efficacy and minimize toxic potential. The climate that allowed the propagation of the "therapeutic orphan" concept is now mostly of historical perspective. Nevertheless, the negative impact of this concept continues to linger due to continued propagation of many, now outdated myths surrounding the effective study of optimal drug dosing in pediatrics. Advances in clinical medicine combined with the advances in study design, sampling, and analysis has dramatically improved the paradigm for clinical pharmacology research in infants and children. Capitalizing upon and thoughtfully using these many advances while dispelling these myths will result in greater research focused on optimal drug therapy in pediatric practice.

Entities:  

Year:  2011        PMID: 22477819      PMCID: PMC3136233     

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  42 in total

1.  The pharmacokinetics of teicoplanin in infants and children.

Authors:  M D Reed; T S Yamashita; C M Myers; J L Blumer
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Pharmacokinetics of metoclopramide in neonates.

Authors:  G L Kearns; J N van den Anker; M D Reed; J L Blumer
Journal:  J Clin Pharmacol       Date:  1998-02       Impact factor: 3.126

3.  Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis.

Authors:  J L Blumer; S C Aronoff; C M Myers; C A O'Brien; J D Klinger; M D Reed
Journal:  Dev Pharmacol Ther       Date:  1985

4.  Comparison of the efficacy and safety of ceftriaxone to ampicillin/chloramphenicol in the treatment of childhood meningitis.

Authors:  S C Aronoff; M D Reed; C A O'Brien; J L Blumer
Journal:  J Antimicrob Chemother       Date:  1984-02       Impact factor: 5.790

5.  The clinical pharmacology of vancomycin in seriously ill preterm infants.

Authors:  M D Reed; R M Kliegman; J S Weiner; M Huang; T S Yamashita; J L Blumer
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

6.  Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age.

Authors:  Jeffrey L Blumer; Robert L Findling; Weichung Joe Shih; Christina Soubrane; Michael D Reed
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

7.  Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; J S Bertino; C M Myers; T S Yamashita; J L Blumer
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

8.  An evaluation of optimal sampling strategy and adaptive study design.

Authors:  G L Drusano; A Forrest; M J Snyder; M D Reed; J L Blumer
Journal:  Clin Pharmacol Ther       Date:  1988-08       Impact factor: 6.875

Review 9.  Acetaminophen intoxication and length of treatment: how long is long enough?

Authors:  Todd Kociancic; Michael D Reed
Journal:  Pharmacotherapy       Date:  2003-08       Impact factor: 4.705

10.  Efficacy and safety of ceftriaxone in serious pediatric infections.

Authors:  S C Aronoff; D Murdell; C A O'Brien; J D Klinger; M D Reed; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

View more
  1 in total

Review 1.  Educational paper: do we need neonatal clinical pharmacologists?

Authors:  Karel Allegaert; Jean Paul Langhendries; John N van den Anker
Journal:  Eur J Pediatr       Date:  2012-05-16       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.